Tvardi Therapeutics (TVRD) Cash from Operations: 2013-2017
Historic Cash from Operations for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2017 value amounting to -$11.4 million.
- Tvardi Therapeutics' Cash from Operations rose 13.46% to -$11.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$54.8 million, marking a year-over-year decrease of 15.72%. This contributed to the annual value of -$60.9 million for FY2024, which is 33.84% up from last year.
- Per Tvardi Therapeutics' latest filing, its Cash from Operations stood at -$11.4 million for Q4 2017, which was down 15.86% from -$9.9 million recorded in Q3 2017.
- In the past 5 years, Tvardi Therapeutics' Cash from Operations registered a high of $13.2 million during Q2 2013, and its lowest value of -$21.6 million during Q1 2017.
- Over the past 3 years, Tvardi Therapeutics' median Cash from Operations value was -$10.6 million (recorded in 2017), while the average stood at -$10.3 million.
- In the last 5 years, Tvardi Therapeutics' Cash from Operations rose by 28.43% in 2015 and then crashed by 216.41% in 2016.
- Tvardi Therapeutics' Cash from Operations (Quarterly) stood at -$5.1 million in 2013, then decreased by 15.01% to -$5.8 million in 2014, then climbed by 28.43% to -$4.2 million in 2015, then tumbled by 216.41% to -$13.2 million in 2016, then grew by 13.46% to -$11.4 million in 2017.
- Its Cash from Operations was -$11.4 million in Q4 2017, compared to -$9.9 million in Q3 2017 and -$11.9 million in Q2 2017.